Loading stock data…
CLRB
$2.69+0.09 (+3.46%)
Market ClosedLast close May 1
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cellectar Biosciences, Inc. in the Healthcare sector is trading at $2.69. The stock is currently near its 52-week low of $2.43, remaining 29.0% below its 200-day moving average. Technical signals show neutral RSI of 48 and bearish MACD signal, explaining why CLRB maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.69
Potential Upside
5%
Whystock Fair Value$2.82
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$12.00+346.1%
Range$10.00 – $14.00
Fundamentals
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.81M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-255.25%
Volume
Today's trading volume
36,210
Recent News
Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary
Moby summary of Cellectar Biosciences, Inc.'s Q4 2025 earnings call
Cellectar (CLRB) Q4 2025 Earnings Call Transcript
Need a quote from a Motley Fool analyst? Jim Caruso, President and CEO, who will provide an overview of the company's progress before turning the call over to Chad Kolean, CFO, for a financial review of the quarter and the year. Following this, Jarrod Longcor, Chief Operating Officer, will give an update on the company's progress and plans for its promising clinical development pipeline of radiopharmaceuticals.
Cellectar Biosciences Inc (CLRB) Q3 2025 Earnings Call Highlights: Strategic Advances and ...
Cellectar Biosciences Inc (CLRB) progresses with regulatory approvals and partnerships, while navigating financial hurdles for future growth.
Cellectar Says FDA Grants Rare Pediatric Drug Designation for Iopofosine in High-Grade Glioma
Cellectar Biosciences (CLRB) said Monday that the US Food and Drug Administration has granted its in
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.